Lantheus Holdings (NASDAQ: LNTH) reported Q1 EPS of $0.36, $0.09 better than the analyst estimate of $0.27. Revenue for the quarter came in at $90.7 million versus the consensus estimate of $91.2 million.

• Worldwide revenue of $90.7 million for the first quarter 2020, representing an increase of 4.8% over the prior year period
• Net income of $3.3 million for the first quarter 2020, representing a decrease of 66.5% from the prior year period
• GAAP diluted EPS of $0.08 for the first quarter 2020, representing a decrease of 66.7% from the prior year period; adjusted diluted EPS of $0.36 for the first quarter 2020, representing an increase of 26.1% over the prior year period
• Net cash provided by operating activities was $9.4 million for the first quarter 2020. Free cash flow of $6.7 million for the first quarter 2020
• Due to uncertain COVID-19 impact, 2020 guidance withdrawn

“First and foremost, Lantheus is proud to serve the life sciences sector and we want to thank healthcare workers everywhere for their extraordinary commitment in these unprecedented times,” said Mary Anne Heino, President and CEO of Lantheus. “Although our first quarter started with robust customer demand, by mid-March our business began to experience the effects of the COVID-19 pandemic, including the impact of stay-at-home mandates and related safety measures such as the delay of elective medical procedures. Despite this, we were still able to achieve revenues near the top end of our guidance and exceeded that for adjusted earnings per share. Although we cannot predict the magnitude or duration of the pandemic’s impact, with our available liquidity and prudent expense management, including previously announced work week and salary reductions, we maintain a state of preparedness to resume full business activities to support our customers as business conditions allow.”

For earnings history and earnings-related data on Lantheus Holdings (LNTH) click here.